CEBPZ and acute myeloid leukemia: Against this background, our multicenter retrospective analysis of 265 CBF-AML patients confirmed a significantly longer OS of 90% vs. 80% at 2 years with the addition of GO to IC induction, adding an OS benefit of approximately 10%.